BACKGROUND: Anxiety and depression in cancer patients are associated with poor health-related quality of life (HRQOL). Clinical interventions to detect and support patients with these symptoms need to be developed and evaluated. We investigated the feasibility of screening with the Hospital Anxiety and Depression Scale (HADS) in a clinical oncology setting. In patients with anxiety or depression symptoms (HADS >7) we explored the use of clinical assessment and psychosocial support and described the development of anxiety, depression and HRQOL during a six-month period. MATERIAL AND METHODS: Four hundred and ninety-five consecutive patients were screened for anxiety and depression at the time of their first visit at an oncology department (baseline). Half of the patients with HADS >7 on any of the two HADS subscales were referred to clinical assessment and psychosocial support (intervention group, IG) and half received standard care (SCG) using a historical control group design. HADS and EORTC QLQ-C30 were completed at baseline and after one, three and six months. RESULTS: One hundred and seventy-six (36%) of 495 patients had anxiety or depression symptoms at screening, HRQOL at baseline was clearly impaired for them. Thirty-six (43%) of 84 IG patients attended clinical assessment, resulting in subsequent psychosocial support for 20 (24%) of them. In the SCG, only five (5%) patients attended clinical assessment after self referral, two received subsequent psychosocial support. Anxiety and depression decreased and HRQOL increased statistically significantly over time although anxiety was frequent and HRQOL impaired during the entire six month period. There were no differences between the SCG and IG regarding anxiety, depression or HRQOL at any time point. CONCLUSION: Systematic screening with HADS is feasible for oncology patients in clinical settings; it identifies patients with persistent symptoms and increases referral to clinical assessment and utilisation of psychosocial support.
BACKGROUND:Anxiety and depression in cancerpatients are associated with poor health-related quality of life (HRQOL). Clinical interventions to detect and support patients with these symptoms need to be developed and evaluated. We investigated the feasibility of screening with the Hospital Anxiety and Depression Scale (HADS) in a clinical oncology setting. In patients with anxiety or depression symptoms (HADS >7) we explored the use of clinical assessment and psychosocial support and described the development of anxiety, depression and HRQOL during a six-month period. MATERIAL AND METHODS: Four hundred and ninety-five consecutive patients were screened for anxiety and depression at the time of their first visit at an oncology department (baseline). Half of the patients with HADS >7 on any of the two HADS subscales were referred to clinical assessment and psychosocial support (intervention group, IG) and half received standard care (SCG) using a historical control group design. HADS and EORTC QLQ-C30 were completed at baseline and after one, three and six months. RESULTS: One hundred and seventy-six (36%) of 495 patients had anxiety or depression symptoms at screening, HRQOL at baseline was clearly impaired for them. Thirty-six (43%) of 84 IG patients attended clinical assessment, resulting in subsequent psychosocial support for 20 (24%) of them. In the SCG, only five (5%) patients attended clinical assessment after self referral, two received subsequent psychosocial support. Anxiety and depression decreased and HRQOL increased statistically significantly over time although anxiety was frequent and HRQOL impaired during the entire six month period. There were no differences between the SCG and IG regarding anxiety, depression or HRQOL at any time point. CONCLUSION: Systematic screening with HADS is feasible for oncology patients in clinical settings; it identifies patients with persistent symptoms and increases referral to clinical assessment and utilisation of psychosocial support.
Authors: Claudia S E W Schuurhuizen; Annemarie M J Braamse; Aartjan T F Beekman; Hanna Bomhof-Roordink; Judith E Bosmans; Pim Cuijpers; Adriaan W Hoogendoorn; Inge R H M Konings; Mecheline H M van der Linden; Elisabeth C W Neefjes; Henk M W Verheul; Joost Dekker Journal: BMC Cancer Date: 2015-04-17 Impact factor: 4.430
Authors: Susanne Mattsson; Sven Alfonsson; Maria Carlsson; Peter Nygren; Erik Olsson; Birgitta Johansson Journal: BMC Cancer Date: 2013-09-11 Impact factor: 4.430
Authors: Susanne Mattsson; Erik Martin Gustaf Olsson; Maria Carlsson; Birgitta Beda Kristina Johansson Journal: J Med Internet Res Date: 2019-04-05 Impact factor: 5.428
Authors: Anna Hauffman; Sven Alfonsson; Anna Bill-Axelson; Leif Bergkvist; Marina Forslund; Susanne Mattsson; Louise von Essen; Peter Nygren; Helena Igelström; Birgitta Johansson Journal: Psychooncology Date: 2020-09-22 Impact factor: 3.894